SCHEMBL302104

SCHEMBL302104

COc1cccc(CN(c2ccc(C(=O)N3CCN(c4ccccc4)CC3)cc2)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.61
HTT P42858 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
KMT2A Q03164 4/20 0.59
HPGD P15428 1/20 0.58
MAPT P10636 5/20 0.55
MEN1 O00255 2/20 0.55
PGR P06401 1/20 0.54
PTGES O14684 1/20 0.54
ALOX5 P09917 1/20 0.54
TAS2R14 Q9NYV8 1/20 0.52
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
MAPK1 P28482 1/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
RECQL P46063 1/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711049 0.95 LMNA (0.62) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL305490 0.89 LMNA (0.56) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL303307 0.88 LMNA (0.71) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL302716 0.86 LMNA (0.73) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1711351 0.86 LMNA (0.62) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1725647 0.86 LMNA (0.53) LMNAHTTSMN1; SMN2KMT2AMAPT
SCHEMBL302112 0.84 LMNA (0.65) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL303551 0.84 LMNA (0.60) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL303907 0.83 LMNA (0.65) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1711093 0.83 LMNA (0.71) LMNAHTTSMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885HTT 3548/4885SMN1; SMN2 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.